UK Innovation & Science Seed Fund

UK Innovation & Science Seed Fund

The UK Innovation & Science Seed Fund (formerly known as The Rainbow Seed Fund) is a £27.1m early-stage venture capital fund building and growing technology companies stemming from the UK’s research base.

We help build companies from great science developed in: public laboratories, science and technology campuses and synthetic biology.

We hold investments in some of the UK’s most innovative companies, in areas as diverse as novel antibiotics, research into Alzheimer’s disease, “green” chemicals and airport security.

 

UKI2S Investments

We’re prepared to invest early and help build a commercial proposition around a technology to attract additional investment needed to get to market.

 

UKI2S Investment Criteria

The Fund’s investment criteria which must be met for us to invest are:

1. Projects and companies arise from world-class research carried out in our partner laboratories across the UK, including those at Rutherford Appleton Laboratory (STFC), Babraham Institute (BBSRC) and Porton Down (Dstl).

Partners

OR

2. Companies are based at or relocating to our partners’ national science and innovation campuses in Harwell Oxford, Babraham Cambridge, Daresbury Warrington and Norwich.


Babraham-Research-Campus-smallHarwell-Oxford  Sci Tech Daresbury 2Norwich Research

 

3. UK Companies working in the field of synthetic biology: Synthetic biology is an exciting new discipline based on the design and engineering of biologically-based parts, novel devices and systems and the redesign of existing, natural biological systems.

 

Economic Value Generated By The Fund Since Its Creation In 2002

A key part of our value in economic terms is in the pivotal early role we play in getting technology companies off the ground, often whilst they are still in the laboratory and before they are ready to spin out. Many of our companies might never have made it, if it had not been for our support and the technologies and services they offer would not have progressed beyond an interesting concept.

 

What We And Our Companies Have Already Achieved

  • We have helped to create over 30 high technology start-up companies in sectors such as health, environmental services, international development and security.
  • We have leveraged over £190 million of private investment into our portfolio companies. This represents a ratio of over £20 for every £1 invested from UKI2S.
  • Over and above co-investment, we have helped generate wider economic impact in the form of salaries, taxes and economic activity in suppliers. Known as “Gross Value Add” (GVA), this measurement, at £5 of GVA for every £1 invested by UKI2S, already shows the benefit of early stage investment, and is forecasted to grow substantially as the companies mature and grow.
  • We have bolstered the UK’s exports – an overwhelming majority of sales in UKI2S companies are overseas and total sales have already reached over £70m.
  • We have helped to create over 240 high value technology-related jobs, a figure that is rising rapidly as the companies accelerate and transition from research into production and sales.
  • The Fund has already had four successful exits and has recycled the funds into new investments. It still holds significant stakes in some very promising companies that we expect to realize in coming years.

In recognition of these achievements, in November 2013 the UKI2S received an additional £10M investment to support the commercialisation of synthetic biology technologies.

This funding was in response to the Synthetic Biology Roadmap, which sets out plans to harness opportunities in the field of synthetic biology. Synthetic biology is one of the eight great technologies highlighted by the UK government as an area of wide-ranging significance and potential economic importance, and in which the UK’s research base is particularly strong.

 

Additional Background

 

The UK Innovation & Science Seed Fund is independently managed by Dr. Andrew Muir and Mark White at Midven.

More information on the Fund can be found at: www.ukinnovationscienceseedfund.co.uk

 

Fund Facts

Current As At: 1st January 2018

Fund Amount £27.1m

4 Profitable Exits

37 Companies

Fund Managers

Associated Investments

Watch


Relevant News

Scientists scramble to stop bananas being killed off

Banana plantations in Australia, south-east Asia, Africa and the Middle East have been ravaged by…

read more

Eagle Genomics raises $1m in funding first close and announces senior leadership changes

Software leader in the field of genomic data and bioinformatics analysis poised for growth 30…

read more

Rainbow Seed Fund Backs Pireta

A Smart Textiles Technology Developed at the National Physical Laboratory London – 17 October 2017 Rainbow…

read more

Nemesis Bioscience Closes Funding Round And Begins Preclinical Programmes

8th May 2017 Nemesis Bioscience today announced the successful completion of its latest funding round,…

read more

Rainbow Seed Fund Backs New STFC Spin Out MIRICO

11 May 2016 Spin out from UK publicly-funded research develops novel laser spectroscopy for environmental,…

read more

Crescendo Biologics Appoints Dr Barbara Fleck as Head of Intellectual Property

Cambridge, UK: 2 February 2016 – Crescendo Biologics Limited (Crescendo), the drug discovery and developer…

read more

Contego Announces Selection Into Accenture's Fintech Innovation Lab London

11th January 2016 Contego CEO Adrian Black is looking forward to working in the collaborative…

read more

Crescendo Biologics Appoints Dr Kevin Johnson as Chairman

Antibody veteran joins new CEO as Crescendo redirects strategy to Oncology focus  Cambridge, UK: 17…

read more

Crescendo Biologics Launches New Strategy In Oncology Drug Discovery & Development

16 October 2015 Crescendo Biologics Limited, the drug discovery and developer of Humabody™ VH therapeutics,…

read more

Case Studies

Case Study - Synthace

Synthace London-based Synthace provides next-generation software and processes to exponentially improve productivity in bioscience, enabling…

read more

Case Study - Tokamak Energy

Summary: Tokamak Energy is working on nuclear fusion, the long-awaited holy grail of the energy…

read more
Your browser is out-of-date!

Update your browser to view this website correctly.Update my browser now

×